Clinical Trial Update: Study of Safety and Efficacy of C-CAR011 in B-NHL Patients [Phase 1]

View source ↗

Summary

A Phase 1 study is evaluating the safety and efficacy of C-CAR011 in patients with refractory or relapsed B-cell non-Hodgkin lymphoma. The current trial status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• C-CAR011

Snippet

Sponsor: Shanghai AbelZeta Ltd. | Conditions: Refractory or Relapsed Non-Hodgkin Lymphoma | Phase 1 | Status: UNKNOWN